![Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV1) in cystic fibrosis patients receiving ivacaftor treatment - Journal of Cystic Fibrosis Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV1) in cystic fibrosis patients receiving ivacaftor treatment - Journal of Cystic Fibrosis](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/7eee42ee-75a9-4421-a642-e9883fcddb44/gr3_lrg.jpg)
Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV1) in cystic fibrosis patients receiving ivacaftor treatment - Journal of Cystic Fibrosis
![Qué beneficio tiene AMX 0035, el medicamento para la ELA que Esteban Bullrich pidió aprobar en Argentina - Noticias de Bariloche Qué beneficio tiene AMX 0035, el medicamento para la ELA que Esteban Bullrich pidió aprobar en Argentina - Noticias de Bariloche](https://www.noticiasdebariloche.com.ar/wp-content/uploads/2022/06/MUDVN2PTXZGTBO4BJGOJK4CMYY.jpg)
Qué beneficio tiene AMX 0035, el medicamento para la ELA que Esteban Bullrich pidió aprobar en Argentina - Noticias de Bariloche
![Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV1) in cystic fibrosis patients receiving ivacaftor treatment - Journal of Cystic Fibrosis Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV1) in cystic fibrosis patients receiving ivacaftor treatment - Journal of Cystic Fibrosis](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/5036c5ad-7e6a-4dff-9881-2b7ae647a3cd/gr4.jpg)
Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV1) in cystic fibrosis patients receiving ivacaftor treatment - Journal of Cystic Fibrosis
![Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)‐CFTR treated with ivacaftor—Changes in microbiological parameters - Millar - 2018 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)‐CFTR treated with ivacaftor—Changes in microbiological parameters - Millar - 2018 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/cc1cb340-cf1d-460e-aa8a-1d964efa1ddf/jcpt12616-fig-0001-m.jpg)